AR037806A1 - Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados de acido nicotinico para prescripciones cardiovasculares - Google Patents
Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados de acido nicotinico para prescripciones cardiovascularesInfo
- Publication number
- AR037806A1 AR037806A1 ARP990106755A ARP990106755A AR037806A1 AR 037806 A1 AR037806 A1 AR 037806A1 AR P990106755 A ARP990106755 A AR P990106755A AR P990106755 A ARP990106755 A AR P990106755A AR 037806 A1 AR037806 A1 AR 037806A1
- Authority
- AR
- Argentina
- Prior art keywords
- amount
- bile acid
- acid transport
- therapeutic combination
- inhibitor compound
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 230000001225 therapeutic effect Effects 0.000 abstract 6
- 239000003613 bile acid Substances 0.000 abstract 4
- 229940077672 Ileal bile acid transport inhibitor Drugs 0.000 abstract 2
- 208000008384 ileus Diseases 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 abstract 1
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 abstract 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 abstract 1
- -1 nicotinic acid derivative compound Chemical class 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Combinaciones de compuestos terapéuticos cardiovasculares para la profilaxis o el tratamiento de enfermedades cardiovasculares, que incluyen la hipercolesterolemia, la ateroesclerosis o la hiperlipidemia. Las combinaciones descriptas incluyen un inhibidor del transporte de ácido íleo-biliar combinado con un derivado de ácido nicotínico. Reivindicación 1: Una combinación terapéutica, caracterizada porque comprende una primera cantidad de un compuesto inhibidor del transporte de ácido íleo-biliar y una segunda cantidad de un compuesto derivado de ácido nicotínico donde la primera cantidad y la segunda cantidad juntos comprenden una cantidad anti-hiperlipidémica efectiva, una cantidad anti-ateroesclerótica efectiva o una cantidad anti-hipercolesterolémica efectiva de los compuestos. Reivindicación 2: La combinación terapéutica de la cláusula 1, caracterizada porque el compuesto inhibidor del transporte del ácido íleo-biliar posee la estructura de la fórmula (1), o un enantiómero o un racemato del mismo. Reivindicación 3: La combinación terapéutica de la cláusula 1, caracterizada porque el compuesto inhibidor del transporte de ácido íleo-biliar posee la estructura de fórmula (2), o un enantiómero o racemato del mismo. Reivindicación 4: La combinación terapéutica de la cláusula 1, caracterizada porque el compuesto inhibidor del transporte de ácido íleo-biliar posee la estructura de fórmula (3), o un enantiómero o racemato del mismo, donde el PEG es una cadena polimérica de polietilenglicol con un peso molecular de 3000 a 4000 aproximadamente. Reivindicación 5: La combinación terapéutica de la cláusula 1, caracterizada porque el compuesto inhibidor del transporte de ácido íleo-biliar posee la estructura de fórmula (4), o un enantiómero o racemato del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11395598P | 1998-12-23 | 1998-12-23 | |
| US14255099P | 1999-07-07 | 1999-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037806A1 true AR037806A1 (es) | 2004-12-09 |
Family
ID=26811675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106755A AR037806A1 (es) | 1998-12-23 | 1999-12-23 | Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados de acido nicotinico para prescripciones cardiovasculares |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20030125316A1 (es) |
| EP (1) | EP1140191B1 (es) |
| JP (1) | JP2002533415A (es) |
| KR (1) | KR20010102963A (es) |
| CN (1) | CN1338946A (es) |
| AR (1) | AR037806A1 (es) |
| AT (1) | ATE226448T1 (es) |
| AU (1) | AU776952B2 (es) |
| BR (1) | BR9916567A (es) |
| CA (1) | CA2356664A1 (es) |
| CZ (1) | CZ20012343A3 (es) |
| DE (1) | DE69903661T2 (es) |
| DK (1) | DK1140191T3 (es) |
| EA (1) | EA005030B1 (es) |
| ES (1) | ES2188285T3 (es) |
| HK (1) | HK1044472A1 (es) |
| HU (1) | HUP0104593A3 (es) |
| IL (1) | IL143938A0 (es) |
| MX (1) | MXPA01006467A (es) |
| MY (1) | MY121399A (es) |
| NO (1) | NO20013160L (es) |
| NZ (1) | NZ512533A (es) |
| PL (1) | PL348581A1 (es) |
| PT (1) | PT1140191E (es) |
| WO (1) | WO2000038729A1 (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| AU2001247331A1 (en) * | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| NZ531796A (en) | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| HUE030062T2 (en) | 2010-11-08 | 2017-04-28 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| PT2637646T (pt) | 2010-11-08 | 2016-08-17 | Albireo Ab | Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar |
| JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ｐｐａｒ活性化剤 |
| US10426765B2 (en) * | 2012-06-15 | 2019-10-01 | Conaris Research Institute Ag | Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| TWI691331B (zh) | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| JP6954927B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CA3011565C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| EP3921027B1 (en) | 2019-02-06 | 2023-07-19 | Albireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| ES2937153T3 (es) | 2019-02-06 | 2023-03-24 | Albireo Ab | Compuestos de benzotiadiazepinas y su uso como moduladores de ácidos biliares |
| TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| HUE065571T2 (hu) | 2019-12-04 | 2024-06-28 | Albireo Ab | Benzotia(di)azepin vegyületek és alkalmazásuk epesav modulátorként |
| AR120683A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| ES2972045T3 (es) * | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
-
1999
- 1999-12-17 JP JP2000590680A patent/JP2002533415A/ja active Pending
- 1999-12-17 HU HU0104593A patent/HUP0104593A3/hu unknown
- 1999-12-17 EA EA200100703A patent/EA005030B1/ru not_active IP Right Cessation
- 1999-12-17 PL PL99348581A patent/PL348581A1/xx not_active Application Discontinuation
- 1999-12-17 NZ NZ512533A patent/NZ512533A/xx unknown
- 1999-12-17 AU AU23481/00A patent/AU776952B2/en not_active Ceased
- 1999-12-17 KR KR1020017008067A patent/KR20010102963A/ko not_active Application Discontinuation
- 1999-12-17 CZ CZ20012343A patent/CZ20012343A3/cs unknown
- 1999-12-17 AT AT99967141T patent/ATE226448T1/de not_active IP Right Cessation
- 1999-12-17 MX MXPA01006467A patent/MXPA01006467A/es not_active Application Discontinuation
- 1999-12-17 PT PT99967141T patent/PT1140191E/pt unknown
- 1999-12-17 CA CA002356664A patent/CA2356664A1/en not_active Abandoned
- 1999-12-17 ES ES99967141T patent/ES2188285T3/es not_active Expired - Lifetime
- 1999-12-17 DE DE69903661T patent/DE69903661T2/de not_active Expired - Fee Related
- 1999-12-17 DK DK99967141T patent/DK1140191T3/da active
- 1999-12-17 EP EP99967141A patent/EP1140191B1/en not_active Revoked
- 1999-12-17 BR BR9916567-8A patent/BR9916567A/pt not_active IP Right Cessation
- 1999-12-17 WO PCT/US1999/027950 patent/WO2000038729A1/en not_active Application Discontinuation
- 1999-12-17 CN CN99816327A patent/CN1338946A/zh active Pending
- 1999-12-17 IL IL14393899A patent/IL143938A0/xx unknown
- 1999-12-22 MY MYPI99005678A patent/MY121399A/en unknown
- 1999-12-23 AR ARP990106755A patent/AR037806A1/es unknown
-
2001
- 2001-06-22 NO NO20013160A patent/NO20013160L/no not_active Application Discontinuation
-
2002
- 2002-08-21 HK HK02106126.2A patent/HK1044472A1/zh unknown
- 2002-09-18 US US10/245,507 patent/US20030125316A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1140191B1 (en) | 2002-10-23 |
| PT1140191E (pt) | 2003-01-31 |
| HUP0104593A3 (en) | 2004-10-28 |
| DE69903661T2 (de) | 2003-07-03 |
| MXPA01006467A (es) | 2004-03-10 |
| CN1338946A (zh) | 2002-03-06 |
| NZ512533A (en) | 2004-02-27 |
| CZ20012343A3 (cs) | 2001-12-12 |
| IL143938A0 (en) | 2002-04-21 |
| EP1140191A1 (en) | 2001-10-10 |
| AU776952B2 (en) | 2004-09-30 |
| KR20010102963A (ko) | 2001-11-17 |
| EA005030B1 (ru) | 2004-10-28 |
| HUP0104593A2 (hu) | 2002-03-28 |
| CA2356664A1 (en) | 2000-07-06 |
| NO20013160L (no) | 2001-08-21 |
| MY121399A (en) | 2006-01-28 |
| DK1140191T3 (da) | 2003-02-24 |
| WO2000038729A1 (en) | 2000-07-06 |
| PL348581A1 (en) | 2002-06-03 |
| AU2348100A (en) | 2000-07-31 |
| JP2002533415A (ja) | 2002-10-08 |
| BR9916567A (pt) | 2001-12-11 |
| NO20013160D0 (no) | 2001-06-22 |
| HK1044472A1 (zh) | 2002-10-25 |
| US20030125316A1 (en) | 2003-07-03 |
| ATE226448T1 (de) | 2002-11-15 |
| ES2188285T3 (es) | 2003-06-16 |
| DE69903661D1 (de) | 2002-11-28 |
| EA200100703A1 (ru) | 2001-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037806A1 (es) | Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados de acido nicotinico para prescripciones cardiovasculares | |
| AR022023A1 (es) | Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados del acido fibrico para prescripciones cardiovasculares | |
| AR022022A1 (es) | Combinaciones de inhibidores del transporte de acido ileo-biliar con agentes secuestrantes de acido biliar, para prescripciones cardiovasculares | |
| AR048891A2 (es) | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv | |
| UY25322A1 (es) | Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis | |
| AR012927A1 (es) | Una composicion farmaceutica, una forma de dosificacion farmaceutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma depresentacion farmaceutica adecuada para la venta comercial | |
| EA200100202A1 (ru) | 4-карбоксиамино-2-замещенные-1,2,3,4-тетрагидрохинолины в качестве сетр-ингибиторов | |
| BR9909893A (pt) | Recipiente para transporte e exposição | |
| AR012172A2 (es) | Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento | |
| AR046126A1 (es) | Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
| ATE386508T1 (de) | Feste orale dosierungsform enthaltend einen resorptionsverstärker | |
| UY27300A1 (es) | Nuevos derivados de quinolina | |
| CA2478374A1 (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
| HN2001000224A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. | |
| AR004700A1 (es) | 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento | |
| ES2171590T3 (es) | Composicion farmaceutica para el tratamiento de rinitis agudas, que contiene un simpatomimetico y pantotenol y/o acido pantotenico. | |
| EA199800023A1 (ru) | Фармацевтическая композиция, содержащая ингибитор протеиназы и моноглицерид | |
| PA8426801A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis. | |
| ES2090244T3 (es) | Procedimiento para prevenir, estabilizar u ocasionar la regresion de la aterosclerosis usando una combinacion de un medicamento para disminuir el colesterol y un inhibidor de la ace. | |
| CO5070569A1 (es) | Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen | |
| TR200400228T4 (tr) | Psöryazinin tedavisinde kullanılacak maddeler | |
| BR0109483A (pt) | Pró-drogas de derivados de imidazopiridina | |
| EA200100947A1 (ru) | Жевательные таблетки с высоким содержанием n-ацетилцистеина | |
| AR002759A1 (es) | Composiciones farmaceuticas en dosis unitarias, que incluyen inhibidores de proteinasa. | |
| PT1216057E (pt) | Solucao de calcitriol estavel para ser embalada em frascos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |